Trial Profile
A Randomized, Double-blind, Parallel-group Study of Fluticasone Propionate/Salmeterol Combination (FSC 250/50mcg) Twice Daily and Salmeterol (SAL 50mcg) Twice Daily to Validate a New Shortness of Breath Questionnaire in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Salmeterol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 26 Feb 2015 New trial record